Francesca Gay

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6520309/publications.pdf

Version: 2024-02-01

167 papers	10,610 citations	57758 44 h-index	34986 98 g-index
167 all docs	167 docs citations	167 times ranked	8335 citing authors

#	Article	IF	Citations
1	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Journal of Clinical Oncology, 2022, 40, 3132-3150.	1.6	13
2	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplantation and Cellular Therapy, 2022, 28, 284-293.	1.2	11
3	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia, 2022, 36, 1371-1376.	7.2	81
4	The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726.	2.7	1
5	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 2022, 40, 3406-3418.	1.6	115
6	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery, 2022, 3, 273-284.	5.0	24
7	Melflufen for the treatment of multiple myeloma. Expert Review of Clinical Pharmacology, 2022, 15, 371-382.	3.1	3
8	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3120-3131.	1.6	29
9	Meta-analysis of ciltacabtagene autoleucel versus physicianâ€™s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. Current Medical Research and Opinion, 2022, 38, 1759-1767.	1.9	5
10	Standardization of ¹⁸F-FDGâ€“PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 116-125.	1.6	85
11	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	7.2	69
12	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia, 2021, 35, 1732-1744.	7.2	5
13	Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e21-e24.	0.4	2
14	Expert review on softâ€tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	2.5	67
15	When and How to Treat Relapsed Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 358-375.	3.8	9
16	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
17	Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction. Cancers, 2021, 13, 1631.	3.7	9
18	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. Clinical Cancer Research, 2021, 27, 3695-3703.	7.0	7

#	Article	IF	Citations
19	MRD Assessment in Multiple Myeloma: Progress and Challenges. Current Hematologic Malignancy Reports, 2021, 16, 162-171.	2.3	29
20	Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 645678.	2.4	8
21	LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving â‰¥3 prior lines of therapy.. Journal of Clinical Oncology, 2021, 39, 8041-8041.	1.6	6
22	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. Blood Cancer Journal, 2021, 11, 106.	6.2	31
23	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. Cancer, 2021, 127, 3413-3421.	4.1	4
24	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 2021, 106, 2799-2812.	3.5	22
25	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	7.0	26
26	Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved?. Leukemia Research, 2021, 107, 106592.	0.8	1
27	The role of autologous stem-cell transplantation in multiple myeloma in 2021. Current Opinion in Oncology, 2021, 33, 642-647.	2.4	5
28	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 3613-3622.	1.6	25
29	Antibody-drug conjugates: when chemotherapy meets immuno-oncology. Lancet Haematology,the, 2021, 8, e778-e779.	4.6	1
30	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Reviews, 2021, 49, 100808.	5.7	27
31	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology,the, 2021, 8, e934-e946.	4.6	46
32	Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2021, 138, 1676-1676.	1.4	2
33	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 1705-1720.	10.7	120
34	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica, 2020, 105, 193-200.	3.5	29
35	Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report. Acta Haematologica, 2020, 143, 481-485.	1.4	0
36	Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. Cancers, 2020, 12, 15.	3.7	39

#	Article	IF	Citations
37	Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. Frontiers in Oncology, 2020, 10, 607571.	2.8	0
38	Checkpoint inhibitors and myeloma: promises, deadlocks and new directions. Annals of Translational Medicine, 2020, 8, 777-777.	1.7	3
39	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood, 2020, 136, 3033-3040.	1.4	146
40	Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. Clinical Cancer Research, 2020, 26, 4832-4841.	7.0	33
41	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e247-e255.	2.0	5
42	Autologous haematopoietic stem-cell transplantation versus bortezomibâ€“melphalanâ€“prednisone, with or without bortezomibâ€“lenalidomideâ€“dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematology,the, 2020, 7, e456-e468.	4.6	244
43	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer Journal, 2020, 10, 40.	6.2	15
44	Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?. Lancet Haematology,the, 2020, 7, e355-e357.	4.6	10
45	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 2020, 34, 2000-2011.	7.2	109
46	Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. Blood, 2020, 136, 35-37.	1.4	37
47	Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity. Blood, 2020, 136, 12-13.	1.4	12
48	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. Blood, 2020, 136, 37-38.	1.4	16
49	Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM).. Journal of Clinical Oncology, 2020, 38, 8533-8533.	1.6	11
50	Melflufen: A Peptideâ€“Drug Conjugate for the Treatment of Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 3120.	2.4	35
51	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. Cancers, 2019, 11, 1735.	3.7	7
52	Do we need cytogenetics in the followâ€up of multiple myeloma?. British Journal of Haematology, 2019, 185, 399-401.	2.5	3
53	Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy. Cancers, 2019, 11, 622.	3.7	20
54	Redefining the treatment paradigm for multiple myeloma. Lancet Oncology, The, 2019, 20, 743-744.	10.7	2

#	Article	IF	Citations
55	CyTOFÂ®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 416-418.	1.5	4
56	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN 503): final results of an openâ€label, phase 1/2 study. British Journal of Haematology, 2019, 186, e35-e39.	2.5	12
57	Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. Cancers, 2019, 11, 2015.	3.7	26
58	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
59	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. Blood, 2019, 134, 693-693.	1.4	18
60	Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.. Journal of Clinical Oncology, 2019, 37, 8002-8002.	1.6	67
61	Bortezomib, lenalidomide, and dexamethasone (VRd) Â± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).. Journal of Clinical Oncology, 2019, 37, TPS8055-TPS8055.	1.6	31
62	Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. Current Medicinal Chemistry, 2019, 26, 5968-5981.	2.4	6
63	Moving Toward Continuous Therapy in Multiple Myeloma. Clinical Hematology International, 2019, 1, 189.	1.7	5
64	The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. Blood, 2019, 134, 5549-5549.	1.4	1
65	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1357-1366.	2.5	8
66	Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?. Annals of Hematology, 2018, 97, 387-400.	1.8	21
67	Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian) Tj ETQq1 1 0.784314 rgBT /Overlock 712-719.	6.4	95
68	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	7.2	68
69	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica, 2018, 103, 197-211.	3.5	110
70	CD38 as an immunotherapeutic target in multiple myeloma. Expert Opinion on Biological Therapy, 2018, 18, 1209-1221.	3.1	27
71	Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2749.	4.8	41
72	Special problems in the management of elderly patients with multiple myeloma. European Journal of Internal Medicine, 2018, 58, 64-69.	2.2	1

#	Article	IF	Citations
73	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. Critical Reviews in Oncology/Hematology, 2018, 132, 9-16.	4.4	13
74	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	3.5	86
75	Cardiovascular adverse events in modern myeloma therapy â€“ Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica, 2018, 103, 1422-1432.	3.5	70
76	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 2018, 32, 1883-1898.	7.2	81
77	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	7.1	67
78	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia, 2018, 32, 1697-1712.	7.2	83
79	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. Blood, 2018, 132, 257-257.	1.4	20
80	Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2018, 132, 121-121.	1.4	46
81	Novel investigational drugs active as single agents in multiple myeloma. Expert Opinion on Investigational Drugs, 2017, 26, 699-711.	4.1	13
82	Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. European Journal of Haematology, 2017, 98, 289-295.	2.2	2
83	Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 471-478.	0.4	34
84	Lenalidomide and lowâ€dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. American Journal of Hematology, 2017, 92, 244-250.	4.1	19
85	Multiple myeloma. Nature Reviews Disease Primers, 2017, 3, 17046.	30.5	812
86	Plasma cell leukemia: update on biology and therapy. Leukemia and Lymphoma, 2017, 58, 1538-1547.	1.3	36
87	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Journal of Clinical Oncology, 2017, 35, 3279-3289.	1.6	535
88	Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget, 2017, 8, 5924-5935.	1.8	33
89	Emerging drugs and combinations to treat multiple myeloma. Oncotarget, 2017, 8, 60656-60672.	1.8	39
90	Autologous transplant for myeloma: when the old meets the new. Oncotarget, 2017, 8, 90618-90619.	1.8	0

#	Article	IF	Citations
91	Stem Cell Transplantation in Multiple Myeloma. Current Cancer Drug Targets, 2017, 17, 769-781.	1.6	2
92	Nuances in the Management of Older People With Multiple Myeloma. Current Hematologic Malignancy Reports, 2016, 11, 241-251.	2.3	11
93	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood, 2016, 127, 681-695.	1.4	179
94	Treatment of Newly Diagnosed Elderly Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 123-143.	0.5	9
95	Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 414-421.	6.4	92
96	Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. Blood, 2016, 128, 3334-3334.	1.4	5
97	Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. Blood, 2016, 128, 992-992.	1.4	0
98	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. Blood, 2016, 128, 995-995.	1.4	0
99	Prognostic Implication of Somatic Mutations By Next Generation Sequencing: An Analysis from the Mmrf Commpass Study in Newly Diagnosed Multiple Myeloma Patients. Blood, 2016, 128, 2079-2079.	1.4	0
100	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dellâ€™Adulto Multiple Myeloma Working Party study. Stem Cell Research and Therapy, 2015, 6, 64.	5.5	25
101	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 2015, 33, 2863-2869.	1.6	1,525
102	The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents. Drugs, 2015, 75, 367-375.	10.9	5
103	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica, 2015, 100, 1254-1266.	3.5	289
104	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 3459-3466.	1.6	138
105	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1617-1629.	10.7	289
106	Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective?. Biology of Blood and Marrow Transplantation, 2015, 21, 1705-1706.	2.0	1
107	Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. Blood, 2015, 126, 392-392.	1.4	4
108	Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood, 2015, 126, 1974-1974.	1.4	0

#	Article	IF	Citations
109	Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study. Blood, 2015, 126, 1760-1760.	1.4	1
110	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica, 2014, 99, 984-996.	3.5	124
111	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	3.5	185
112	MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. British Journal of Haematology, 2014, 164, 841-850.	2.5	20
113	Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs, 2014, 23, 1193-1209.	4.1	6
114	Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. Expert Opinion on Biological Therapy, 2014, 14, 1127-1144.	3.1	13
115	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. New England Journal of Medicine, 2014, 371, 895-905.	27.0	683
116	High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica, 2014, 99, e14-e16.	3.5	42
117	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. Haematologica, 2014, 99, 1611-1617.	3.5	29
118	Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials. Blood, 2014, 124, 198-198.	1.4	3
119	In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide. Blood, 2014, 124, 3394-3394.	1.4	2
120	Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.. Journal of Clinical Oncology, 2014, 32, 8515-8515.	1.6	6
121	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. Blood, 2014, 124, 4740-4740.	1.4	0
122	Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1517-1527.	3.3	17
123	Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood, 2013, 122, 1376-1383.	1.4	74
124	Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica, 2013, 98, 87-94.	3.5	73
125	Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients. Blood, 2013, 122, 2089-2089.	1.4	11
126	A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients. Blood, 2013, 122, 687-687.	1.4	15

#	Article	IF	Citations
127	A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. Blood, 2013, 122, 763-763.	1.4	20
128	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. Blood, 2013, 122, 3126-3126.	1.4	2
129	Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1209-1222.	3.3	9
130	Early versus delayed autologous transplantation after immunomodulatory agentsâ€based induction therapy in patients with newly diagnosed multiple myeloma. Cancer, 2012, 118, 1585-1592.	4.1	106
131	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. Blood, 2012, 120, 2921-2921.	1.4	0
132	Management of Myeloma: An Italian Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S82-S86.	0.4	0
133	A new combination for advanced multiple myeloma. Lancet Oncology, The, 2011, 12, 207-208.	10.7	0
134	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood, 2011, 117, 3025-3031.	1.4	247
135	The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomibâ€containing regimens. Cancer, 2011, 117, 1884-1890.	4.1	13
136	Management of older patients with multiple myeloma. Blood Reviews, 2011, 25, 65-73.	5.7	31
137	Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood, 2010, 115, 1343-1350.	1.4	119
138	Management of disease- and treatment-related complications in patients with multiple myeloma. Medical Oncology, 2010, 27, 43-52.	2.5	25
139	Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. European Journal of Haematology, 2010, 85, 200-208.	2.2	8
140	Clarithromycin (Biaxin)â€lenalidomideâ€lowâ€dose dexamethasone (BiRd) versus lenalidomideâ€lowâ€dose dexamethasone (Rd) for newly diagnosed myeloma. American Journal of Hematology, 2010, 85, 664-669.	4.1	49
141	Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. Journal of Clinical Oncology, 2010, 28, 800-807.	1.6	166
142	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica, 2010, 95, 1144-1149.	3.5	40
143	Towards a new standard of care for patients with myeloma?. Lancet Oncology, The, 2010, 11, 3-4.	10.7	3
144	A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients. Blood, 2010, 116, 1940-1940.	1.4	5

#	Article	IF	Citations
145	How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology American Society of Hematology Education Program, 2009, 2009, 566-577.	2.5	36
146	Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. Leukemia Research, 2009, 33, e145-e149.	0.8	11
147	Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results. Clinical Lymphoma and Myeloma, 2009, 9, 145-150.	1.4	36
148	New Combination Approaches for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2009, 9, S42-S43.	1.4	0
149	First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie) Tj ETQq1 1 0.784314 rgBT /Overl 10, 906-922.	2.1	9
150	Depth of Response with Stem Cell Transplantation and Outcome for Multiple Myeloma in the Era of Novel Agents.. Blood, 2009, 114, 1228-1228.	1.4	1
151	Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 2868-2868.	1.4	3
152	Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.. Blood, 2009, 114, 3419-3419.	1.4	1
153	The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.. Blood, 2009, 114, 3887-3887.	1.4	5
154	Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.. Blood, 2009, 114, 2877-2877.	1.4	0
155	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 3884-3884.	1.4	0
156	Update on Recent Developments for Patients with Newly Diagnosed Multiple Myeloma. Annals of the New York Academy of Sciences, 2008, 1138, 19-21.	3.8	10
157	Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 2008, 111, 3968-3977.	1.4	294
158	Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia and Lymphoma, 2008, 49, 2156-2162.	1.3	143
159	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood, 2008, 112, 3107-3114.	1.4	339
160	Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients. Blood, 2008, 112, 159-159.	1.4	17
161	Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results. Blood, 2008, 112, 2768-2768.	1.4	2
162	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMAâ€"Italian Multiple Myeloma Network. Journal of Clinical Oncology, 2007, 25, 4459-4465.	1.6	301

#	Article	IF	Citations
163	Melphalan and its role in the management of patients with multiple myeloma. Expert Review of Anticancer Therapy, 2007, 7, 945-957.	2.4	43
164	Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer, 2007, 109, 2285-2290.	4.1	79
165	Time to first disease progression, but not Î²2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer, 2007, 110, 824-829.	4.1	19
166	Intermediate-Dose Melphalan (100 mg/m2)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 475-477.	1.4	22
167	Bortezomib and Plasma Cell Leukemia.. Blood, 2006, 108, 3546-3546.	1.4	1